Research Paper Volume 13, Issue 10 pp 13405—13420

Inhibition of CXCR2 plays a pivotal role in re-sensitizing ovarian cancer to cisplatin treatment

CXCR2 overexpression correlates to patients’ low overall survival carrying primary EOC. Data from 370 patients diagnosed with serous EOC were obtained from TCGA database for in silico analysis of patients’ overall survival (OS) in relation with the chemokines of interest expression by cancer cells, using the Kaplan-Meier statistical method. (A) Correlation of EOC patients, which tumor cells express low (n=95) or high (n=275) levels of CXCR2 to patients’ OS. Note that patients that carry EOC expressing high levels of CXCR2 had lower overall survival rate in comparison to the ones with low levels of the chemokines receptor (p=0.035). Moreover, overexpression of CXCR2 was identified in 74.32% of the studied patients. (B) Correlation of EOC patients, which tumor cells express low (n=109) or high (n=261) levels of CXCL2 to patients’ overall survival. No significant difference were observed with regard to CXCL2 expression by cancer cells and patients’ overall survival rate (p=0.18). However, overexpression of CXCL2 was seen in 70.54% of patients. (C) Correlation of EOC patients, which tumor cells express low (n=102) or high (n=268) levels of CXCL8 to patient’s overall survival. No significant differences were observed confronting CXCL8 expression by cancer cells to patients’ overall survival rate (p=0.95). Nonetheless, overexpression of CXCL8 was detected in 72.43% of patients. Long rank test was performed to analyse statistical difference amongst the parameters investigated.

Figure 4. CXCR2 overexpression correlates to patients’ low overall survival carrying primary EOC. Data from 370 patients diagnosed with serous EOC were obtained from TCGA database for in silico analysis of patients’ overall survival (OS) in relation with the chemokines of interest expression by cancer cells, using the Kaplan-Meier statistical method. (A) Correlation of EOC patients, which tumor cells express low (n=95) or high (n=275) levels of CXCR2 to patients’ OS. Note that patients that carry EOC expressing high levels of CXCR2 had lower overall survival rate in comparison to the ones with low levels of the chemokines receptor (p=0.035). Moreover, overexpression of CXCR2 was identified in 74.32% of the studied patients. (B) Correlation of EOC patients, which tumor cells express low (n=109) or high (n=261) levels of CXCL2 to patients’ overall survival. No significant difference were observed with regard to CXCL2 expression by cancer cells and patients’ overall survival rate (p=0.18). However, overexpression of CXCL2 was seen in 70.54% of patients. (C) Correlation of EOC patients, which tumor cells express low (n=102) or high (n=268) levels of CXCL8 to patient’s overall survival. No significant differences were observed confronting CXCL8 expression by cancer cells to patients’ overall survival rate (p=0.95). Nonetheless, overexpression of CXCL8 was detected in 72.43% of patients. Long rank test was performed to analyse statistical difference amongst the parameters investigated.